-
Product Insights
NewNet Present Value Model: Oculis Holding AG’s Licaminlimab
Empower your strategies with our Net Present Value Model: Oculis Holding AG's Licaminlimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Oculis Holding AG’s Dexamethasone Acetate
Empower your strategies with our Net Present Value Model: Oculis Holding AG's Dexamethasone Acetate report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Licaminlimab in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Licaminlimab in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Licaminlimab in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: Licaminlimab (OCS-02)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mitapivat Sulfate in Acquired (Autoimmune) Hemolytic Anemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mitapivat Sulfate in Acquired (Autoimmune) Hemolytic Anemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mitapivat Sulfate in Acquired (Autoimmune) Hemolytic Anemia Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SGN-1 in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SGN-1 in Melanoma Drug Details: SGN-1 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dexamethasone Acetate in Cystoid Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dexamethasone Acetate in Cystoid Macular Edema report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dexamethasone Acetate in Cystoid Macular Edema Drug Details: Dexamethasone...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dexamethasone Acetate in Diabetic Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dexamethasone Acetate in Diabetic Macular Edema report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dexamethasone Acetate in Diabetic Macular Edema Drug Details: Dexamethasone acetate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dexamethasone Acetate in Ocular Inflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dexamethasone Acetate in Ocular Inflammation report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dexamethasone Acetate in Ocular Inflammation Drug Details: Dexamethasone acetate (DexNP,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dexamethasone Acetate in Ocular Pain (Eye Pain)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dexamethasone Acetate in Ocular Pain (Eye Pain) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dexamethasone Acetate in Ocular Pain (Eye Pain) Drug...
-
Product Insights
Anterior Uveitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Anterior Uveitis - Drugs In Development, 2023’, provides an overview of the Anterior Uveitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anterior Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...